Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Gross Profit (2016 - 2025)

Vanda Pharmaceuticals (VNDA) has disclosed Gross Profit for 13 consecutive years, with $53.4 million as the latest value for Q4 2025.

  • Quarterly Gross Profit rose 5.51% to $53.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $203.1 million through Dec 2025, up 8.32% year-over-year, with the annual reading at $203.1 million for FY2025, 8.32% up from the prior year.
  • Gross Profit hit $53.4 million in Q4 2025 for Vanda Pharmaceuticals, roughly flat from $53.3 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $63.3 million in Q3 2021 to a low of $35.8 million in Q3 2023.
  • Historically, Gross Profit has averaged $52.1 million across 5 years, with a median of $53.3 million in 2025.
  • Biggest five-year swings in Gross Profit: crashed 39.4% in 2023 and later grew 26.15% in 2024.
  • Year by year, Gross Profit stood at $61.8 million in 2021, then dropped by 5.73% to $58.2 million in 2022, then decreased by 28.21% to $41.8 million in 2023, then increased by 21.01% to $50.6 million in 2024, then rose by 5.51% to $53.4 million in 2025.
  • Business Quant data shows Gross Profit for VNDA at $53.4 million in Q4 2025, $53.3 million in Q3 2025, and $49.9 million in Q2 2025.